» Articles » PMID: 29310641

Health Services Research in Patients with Breast Cancer (CAMISS-prospective): Study Protocol for an Observational Prospective Study

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2018 Jan 10
PMID 29310641
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Though breast cancer remains a major health problem, there is a lack of information on health care provided to patients with this disease and associated costs. In addition, there is a need to update and validate risk stratification tools in Spain. Our purpose is to evaluate the health services provided for breast cancer in Spain, from screening and diagnosis to treatment and prognosis.

Methods: Prospective cohort study involving 13 hospitals in Spain with a follow-up period of up to 5 years after diagnostic biopsy. Eligibility criteria: Patients diagnosed with breast cancer between April 2013 and May 2015 that have consented to participate in the study.

Data Collection: Data will be collected on the following: pre-intervention medical history, biological, clinical, and sociodemographic characteristics, mode of cancer detection, hospital admission, treatment, and outcomes up to 5 years after initial treatment. Questionnaires about quality of life (EuroQoL EQ-5D-5 L, the European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire EORTC QLQ-C30 join to the specific breast cancer module (QLQ-BR23), as well as Hospital Anxiety and Depression Scale were completed by the patients before the beginning of the initial treatment and at the end of follow-up period, 2 years later. The end-points of the study were changes in health-related quality of life, recurrence, complications and readmissions at 2 and 5 years after initial treatment.

Statistical Analysis: Descriptive statistics will be calculated and multivariate models will be used where appropriate to adjust for potential confounders. In order to create and validate a prediction model, split validation and bootstrapping will be performed. Cost analysis will be carried out from the perspective of a national health system.

Discussion: The results of this coordinated project are expected to generate scientifically valid and clinically and socially important information to inform the decision-making of managers and the authorities responsible for ensuring equality in care processes as well in health outcomes. For clinicians, clinical prediction rules will be developed which are expected to serve as the basis for the development of software applications.

Trial Registration: NCT02439554 . Date of registration: May 8, 2015 (retrospectively registered) .

Citing Articles

Adherence to Screening Tests for Gynaecological and Colorectal Cancer in Patients with Diabetes in Spain: A Population-Based Study (2014-2020).

Zeng-Zhang L, de Miguel-Diez J, Lopez-de-Andres A, Jimenez-Garcia R, Ji Z, Meizoso-Pita O J Clin Med. 2024; 13(11).

PMID: 38892758 PMC: 11172449. DOI: 10.3390/jcm13113047.


Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.

Miret C, Orive M, Sala M, Garcia-Gutierrez S, Sarasqueta C, Legarreta M Qual Life Res. 2023; 32(4):989-1003.

PMID: 36630024 PMC: 10063520. DOI: 10.1007/s11136-022-03327-4.


Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program.

Garcia M, Redondo M, Zarcos I, Louro J, Rivas-Ruiz F, Tellez T Eur J Breast Health. 2022; 18(2):182-189.

PMID: 35445174 PMC: 8987861. DOI: 10.4274/ejbh.galenos.2022.2021-11-8.


Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors.

Hernandez L, Arauzo-Bravo M, Gerovska D, Solaun R, Machado I, Balian A Cancers (Basel). 2021; 13(2).

PMID: 33451046 PMC: 7828568. DOI: 10.3390/cancers13020276.


Factors that Influence Treatment Delay for Patients with Breast Cancer.

Padilla-Ruiz M, Zarcos-Pedrinaci I, Rivas-Ruiz F, Garcia-Gutierrez S, Serrano-Aguilar P, Castells X Ann Surg Oncol. 2020; 28(7):3714-3721.

PMID: 33247362 DOI: 10.1245/s10434-020-09409-2.


References
1.
Romero A, Tora-Rocamora I, Bare M, Barata T, Domingo L, Ferrer J . Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs. BMC Cancer. 2016; 16(1):735. PMC: 5025583. DOI: 10.1186/s12885-016-2768-1. View

2.
Sarasqueta C, Martinez-Camblor P, Mendiola A, Martinez-Pueyo I, Michelena M, Basterretxea M . [Breast cancer relative survival after the first recurrence and related prognostic factors]. Med Clin (Barc). 2009; 133(13):489-95. DOI: 10.1016/j.medcli.2009.03.036. View

3.
Arraras J, Arias F, Tejedor M, Pruja E, Marcos M, Martinez E . The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology. 2002; 11(3):249-56. DOI: 10.1002/pon.555. View

4.
Griffiths R, Gleeson M, Valderas J, Danese M . Impact of undetected comorbidity on treatment and outcomes of breast cancer. Int J Breast Cancer. 2014; 2014:970780. PMC: 3943288. DOI: 10.1155/2014/970780. View

5.
Kellen E, Putte G, Van Steen A, Cloes E, Lousbergh D, Buntinx F . Interval cancers in the beginning years of the breast cancer screening programme in the Belgian province of Limburg. Acta Clin Belg. 2008; 63(3):179-84. DOI: 10.1179/acb.2008.028. View